2017 Neonatal Pharmacology


SAT130 - Avastin for ROP: Friend or Foe (Rx = .75 hr.)


Apr 8, 2017 1:30pm ‐ Apr 8, 2017 2:15pm


Credits: None available.

Standard: $15.00
  0       0

Description

Learning Objectives:

  • Learn about appropriate dosing of Bevacizumab for retinopathy of prematurity.
  • Describe the pharmacokinetics of Bevacizumab in infants.
  • Evaluate pros and cons of laser v. Bevacizumab for retinopathy of prematurity.

ACPE Number and CE Hours:

ACPE #0263-000-17-771-L01-P (.75 contact hr.)

Speaker(s):

Credits

  • 0.75 - Pharmacology
  • 1.25 - Physician
  • 1.25 - RN / NP (All RNs/Nurses except CA RNs)
  • 1.25 - CA RN/CA BRN
  • 0.75 - Pharmacist

You must be logged in and own this session in order to post comments.

Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content
token-speaker-name image
token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content